_how-do-genetic-mutations-impact-prostate-cancer-treatment-options.jpg "How Do Genetic Mutations Impact Prostate Cancer Treatment Options? from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 44 sec
✓ Published: 23-Jun-2021
✓ Published: 23-Jun-2021
Description:
How do genetic mutations impact prostate cancer treatment options? Dr. Himisha Beltran shares how information about genetic mutations play into treatment decisions and discusses the role of PARP inhibitor therapies and immunotherapies.nnDr. Himisha Beltran is Director of Translational Research in the Department of Medical Oncology at Dana-Farber Cancer Institute. Learn more about Dr. Beltran, here: https://www.dana-farber.org/find-a-doctor/himisha-beltran/.
How do genetic mutations impact prostate cancer treatment options? Dr. Himisha Beltran shares how information about genetic mutations play into treatment decisions and discusses the role of PARP inhibitor therapies and immunotherapies.nnDr. Himisha Beltran is Director of Translational Research in the Department of Medical Oncology at Dana-Farber Cancer Institute. Learn more about Dr. Beltran, here: https://www.dana-farber.org/find-a-doctor/himisha-beltran/.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_e4-sting-2007.webp "My submission to the E4 stings competition 2007.")
_parp-inhibitor-monotherapy.webp "In this GU CONNECT programme, brought to you by Dr Neal Shore, you’ll follow a patient through their metastatic castration-resistant prostate cancer (mCRPC) journey and explore the clinical implementation of genetic testing and monotherapy treatment with a PARPi.nnWatch the 5-minute animated video and download the accompanying slides for an update on:nn- Efficacy and safety profiles of PARP inhibitors for prostate cancern- The role of genetic testing and how to use it to assess HRRm status and")
_esmo-e-learning-parp-inhibitors-past-present-and-future.webp "ESMO E-Learning: PARP Inhibitors: Past, Present and Future from parp")
_-nicotinamide-mononucleotide-1094-61-7-manufacturer-cofttek.webp "β-Nicotinamide Mononucleotide (1094-61-7) Manufacturer - Coftteknnhttps://www.cofttek.com/product/1094-61-7/nnβ-Nicotinamide Mononucleotide (NMN) SpecificationsnnnnName:nβ-Nicotinamide Mononucleotide (NMN)nnnCAS:n1094-61-7nnnPurityn98%nnnMolecular Formula:nC11H15N2O8PnnnMolecular Weight:n334.2208 g/molnnnMelt Point:n96°CnnnChemical name:n((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphatennnSynonyms:nNicotinamide Mononucleotide; NMN;")
_technics-su-9070-test.webp "parp")
_our-resilient-genome.webp "Our Resilient Genome is a short science animation that tells the story of our DNA, how it is constantly breaking and rebuilding over and over again to keep us alive, and provides a glimpse into the fascinating world of cellular biology.nnThis work has been carried out within the PhysioIllustration project and is funded by NFR (project #218023)nThe Bergen University Fund (Universitetsfondet)nBEK/ Bergen senter for elektronisk kunst bek.nonnContributors and Scientific Advisors:nAnne-Kristin Stavru")
_asco-2018-the-latest-in-bladder-cancer-treatments.webp "Prof Thomas Powles (Barts Cancer institute, London) and Prof Shahrokh F. Shariat (Vienna General Hospital, Germany) discuss the current patient eligibility changes within immuno-oncology following new guidance from EMA/FDA and share their thoughts on emerging neoadjuvant data with checkpoint inhibitors following some investigator initiated trials.nnBoth experts share their views on recently presented data on IDO1 inhibitors and pan-FGFR kinase inhibitors and signpost that future management of ur")
_le-groupe-partouche.webp "http://www.morninglory.biznQuand on a plus confiance en sa banque, rien de mieux que de récuperer son argent pou l’investir sur une couleur…Et pour ca il y a les casinos Partouche ( Eurolist PARP).")
_e4-sting-2007.jpg)
_parp-inhibitor-monotherapy.jpg)
_esmo-e-learning-parp-inhibitors-past-present-and-future.jpg)
_-nicotinamide-mononucleotide-1094-61-7-manufacturer-cofttek.jpg)
_technics-su-9070-test.jpg)
_our-resilient-genome.jpg)
_asco-2018-the-latest-in-bladder-cancer-treatments.jpg)
_le-groupe-partouche.jpg)
![[+]](/images/menu.gif){kind=small}